Skip to content

Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism

Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism: an Open Randomized Controlled Trial Using a Comprehensive Abdomen/Pelvis Computed Tomography

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00773448
Acronym
SOME
Enrollment
862
Registered
2008-10-16
Start date
2008-09-30
Completion date
2015-04-30
Last updated
2015-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism

Keywords

Cancer, Screening

Brief summary

Blood clots in leg veins (deep vein thrombosis) or lung arteries (pulmonary embolism) that happen for no reason (i.e. unexplained) are both called unprovoked venous thromboembolism (VTE). These unexplained blood clots can be the first symptom of cancer. Up to 10% of patients with unexplained blood clots will be diagnosed with cancer within one year of their blood clot diagnosis. These cancers can be found anywhere in the body although the relationship appears stronger with the pancreas, ovary and liver. Cancer testing in patients with blood clots is controversial. There is presently a wide variety of expert opinions and practices. Previous studies showed that a limited cancer screen including a medical history, physical examination, basic blood work and chest X-ray, will find about 90% of cancers. More recent and better designed studies showed that the limited cancer screen misses many cancers and needs to be improved. More extensive cancer testing may find more cancers but is potentially uncomfortable for patients, costs a lot of money and involves a lot of people. The comprehensive computed tomography is less uncomfortable, inexpensive, radiological test made to find many cancers at once. Thus, the scientific question to be asked is: Does a comprehensive computed tomography miss less cancers than a limited cancer screen in patients with blood clots? The main goal of this study is to find out if a comprehensive computed tomography misses less cancers than a limited cancer screen in patients with unexplained blood clots. The second goal of the study is 1) to find out if a comprehensive computed tomography finds more curable cancers than the limited cancer screen; 2) to find out if the patients diagnosed with cancer are still alive and cancer-free after one year (i.e. the patients with curable cancer were treated and are doing well); 3) to prove that a negative comprehensive computed tomography means that the patient will not have cancer and; 4) to find out if a comprehensive computed tomography is well tolerated and safe for patients.

Interventions

DEVICEComprehensive computed tomography of the abdomen/pelvis

Virtual colonoscopy and gastroscopy, a biphasic enhanced CT for hepatoma and renal cell carcinoma, parenchymal pancreatogram with minimum intensity projection (MinIP) reformation for pancreatic carcinoma, and finally uniphasic enhanced CT of distended bladder for bladder and ovarian carcinomas.

OTHERLimited Malignancy Screening

1\) A complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin, LDH); 4) renal function test (creatinine); 5) chest X-ray (if not performed in the past year) In women, a pap smear/pelvic examination (if \> 18 and \< 70 years old and not performed during the past year),a mammogram (\> 50 years old) will be performed if not conducted in last year. Similarly for men, prostate examination +/- PSA testing (\>40 years old) will be performed if not conducted in the past year.

Sponsors

Ottawa Hospital Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with a new diagnosis of unprovoked proximal deep vein thrombosis (DVT) or pulmonary embolism (PE) will be eligible to participate into the study: * Unprovoked VTE is defined as the absence of any of the following predisposing factors: 1. known active cancer; 2. recent (less than 3 months) paralysis, paresis or plaster immobilization of the lower extremities; 3. recently bedridden for period of 3 or more days, or major surgery, within the previous 12 weeks requiring general or regional anaesthesia; 4. previous unprovoked VTE; 5. known thrombophilia (hereditary or acquired) * Proximal DVT is defined as a non-compressibility of any vein segment from the common femoral vein to the trifurcation of the popliteal vein or a persistent intra-luminal filling defect of the iliac, common femoral, superficial femoral or popliteal veins on contrast venography. * Pulmonary embolism is defined as: 1. patients with a high/intermediate pre-test probability (Wells' model \> 4) + high probability V/Q scan; 2. positive pulmonary angiogram; or 3. spiral CT demonstrating intraluminal filling defect in a vessel larger than a segmental artery

Exclusion criteria

Patients will be excluded from the study if they have any of the following criteria: * Age \< 18 years-old; * Refusal or inability to provide informed consent; * Greater than 21 days post diagnosis of idiopathic VTE * Index VTE event of UEDVT or unusual site DVT * Diagnosis of SSPE in the absence of above or below knee DVT * Allergy to contrast media; * Creatinine clearance \< 60 ml/min; * Claustrophobia or agoraphobia; * Weight \> 130 kg; * Diagnosis of ulcerative colitis; and * Diagnosis of glaucoma * Current pregnancy

Design outcomes

Primary

MeasureTime frame
Previously undiagnosed malignancy missed by malignancy screening defined as biopsy proven tissue diagnosis of malignancy diagnosed from the time of malignancy screening completion to the end of the 1 year follow-up period.1 year

Secondary

MeasureTime frame
Overall mortality1 year
Recurrent VTE1 year
Early malignancy: T1-2N0M0 as per the World Health Organization TNM classification system1 year
Incremental cost-effectiveness ratio1 year
Adverse events with cCT1 year
QALYs gained1 year

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026